• For readers wondering whether Danaher stock is starting to look appealing again after a rough stretch, this article focuses squarely on what you are paying versus what you might be getting.
• After closing at US$161.91, the stock is down 5.4% over the past week, 18.3% over the past month, 29.7% year to date, and 16.9% over the last year. Those moves may catch the eye of investors watching for changing risk and return trade offs.
• Recent share price moves sit against a backdrop of ongoing coverage of Danaher as a large US life sciences and diagnostics group and continuing interest in how its portfolio positions it within healthcare and research tools. While short term headlines can add noise, they also prompt investors to reassess what a reasonable price looks like today.
• On Simply Wall St's valuation checklist, Danaher scores a 5 out of 6. This sets up a closer look at different valuation approaches next, and later in the article a way to think about value that goes beyond the usual ratios and models.

Approach 1: Danaher Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value using a required return. It focuses on what you are paying for the underlying cash the business is expected to generate, not just current earnings multiples.

For Danaher, the model uses last twelve month Free Cash Flow of about $5.1b and a 2 Stage Free Cash Flow to Equity approach. Analyst and extrapolated projections suggest FCF reaching $8.1b by 2030, with a series of annual estimates between 2026 and 2035 that are discounted back to today using Simply Wall St’s cash flow projections framework. All cash flows are assessed in $.

Pulling these projections together, the DCF model arrives at an estimated intrinsic value of $227.08 per share. Against the recent share price of $161.91, this comparison implies the stock is trading at a 28.7% discount to the model’s estimate, which points to a material gap between price and projected cash flows.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 28.7%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Danaher Price vs Earnings (P/E)

For a profitable company like Danaher, the P/E ratio is a straightforward way to think about what you are paying for each dollar of current earnings, which is often how the market anchors its view of value.

What counts as a "normal" or "fair" P/E depends on how the market views the company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher risk tends to align with a lower multiple.

Danaher currently trades on a P/E of 31.18x. This sits below the Life Sciences industry average of 34.66x and below the peer group average of 35.13x. This suggests the stock is priced at a lower multiple than many comparable companies.

Simply Wall St’s Fair Ratio concept goes a step further. It estimates what P/E might be reasonable for Danaher given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it is tailored to the company’s profile, it can be more useful than a simple peer or industry comparison.

For Danaher, the Fair Ratio is 29.00x, slightly below the current P/E of 31.18x. This indicates the stock is somewhat overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Danaher Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring your view of Danaher together by linking a simple story about the business to your own revenue, earnings and margin assumptions. This turns those inputs into a Fair Value that you can compare with the current share price, all within an easy tool on Simply Wall St’s Community page. The tool updates as news or earnings arrive and already hosts very different views on Danaher. For example, one investor frames a higher Fair Value closer to about US$310 based on confidence in recurring revenue and future earnings potential, while another anchors nearer US$205 with more caution around policy, bioprocessing demand and funding risks.

Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.